MedEdTalks - Dermatology

This episode explores how emerging interferon-targeted therapies may reshape the treatment of cutaneous lupus erythematosus (CLE). Using a clinical scenario, it explores when earlier use of targeted therapies may help prevent scarring, dyspigmentation, and permanent hair loss; review the evolving roles of agents such as anifrolumab, litifilimab, and enpatoran; and addresses safety, patient preferences, and treatment sequencing. Discussion also highlights the importance of dermatology-rheumatology collaboration and addresses real-world barriers to accessing newer therapies.   To claim CE credit after listening to this episode, go to this link and check the "Already listened on another platform?" box: https://www.vindicocme.com/3cutaneous-lupus-conversations-integrating-targeted-cle-therapies-into-practice-with-drs-victoria-werth-and-maria-dall-era-bltb6ddf349166e5149/overview

In this podcast, expert clinicians explore emerging evidence for interferon-targeted therapies in cutaneous lupus erythematosus (CLE). Faculty review the evolving understanding of interferon signaling in CLE and examine recent clinical data for therapies targeting this pathway, with a focus on how these advances may influence future treatment strategies   To claim CE credit after listening to this episode, go to this link and check the "Already listened on another platform?" box: https://www.vindicocme.com/2cutaneous-lupus-conversations-emerging-evidence-for-interferon-targeted-therapy-with-drs-victoria-werth-and-kenneth-kalunian-blte2f8d1fc948d8ddb/overview

In this podcast, expert clinicians examine the role of type 1 interferon signaling in the pathogenesis of cutaneous lupus erythematosus (CLE) and emerging therapeutic strategies targeting this pathway. Faculty discuss the involvement of plasmacytoid dendritic cells and other immune cells in interferon production and signaling, as well as the rationale for targeting BDCA2, TLR7/8, and downstream mediators of interferon signaling.    To claim CE credit after listening to this episode, go to this link and check the "Already listened on another platform?" box: https://www.vindicocme.com/1cutaneous-lupus-conversations-interferon-focused-strategies-to-treat-cle-with-drs-victoria-werth-and-maria-dall-era-blt12dec68dd5ff6941/overview

In this podcast, expert clinicians will explore shared decision-making strategies to help align treatment selection with individual patient goals, preferences, and expectations.   To claim CE credit after listening to this episode, go to this link and check the "Already listened on another platform?" box: https://www.healio.com/cme/mededtalks/dermatology/20260615/3optimizing-the-use-of-shared-decision-making-in-pso

In this podcast, expert clinicians will discuss updates on emerging oral therapies targeting IL signaling and their impact on PsO care. To claim CE credit after listening to this episode, go to this link and check the "Already listened on another platform?" box: https://www.healio.com/cme/mededtalks/dermatology/20260615/2targeting-interleukins-with-oral-agents

In this podcast, expert clinicians will discuss the current therapeutic landscape and remaining barriers to adequate care for patients with psoriasis.   To claim CE credit after listening to this episode, go to this link and check the "Already listened on another platform?" box: https://www.healio.com/cme/mededtalks/dermatology/20260615/1overcoming-the-barriers-of-biologics-in-psoriasis

In this podcast, expert clinicians engage in a case-based discussion to emphasize the importance of personalized multimodal therapy and multidisciplinary, collaborative care plans. 

In this podcast, expert clinicians engage in a case-based discussion to review treatment options based on the latest evidence for current and emerging therapies for prurigo nodularis (PN).

In this podcast, expert clinicians will discuss the underlying pathophysiology and characteristic features of prurigo nodularis (PN), including its effects on patients' quality of life.

In this podcast, expert clinicians will discuss the emerging treatment options for CSU management.